MARKSANS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg
April 1 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES USP, 100 MG & 200 MG
MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES
Source text: ID:nBSE1ZdcH9
Further company coverage: MARK.NS
April 1 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES USP, 100 MG & 200 MG
MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES
Source text: ID:nBSE1ZdcH9
Further company coverage: MARK.NS
Marksans Pharma Dec-Quarter Consol Net Profit 1.13 Billion Rupees
Feb 5 (Reuters) - Marksans Pharma Ltd MARK.NS:
DEC-QUARTER CONSOL NET PROFIT 1.13 BILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.54 BILLION RUPEES
Source text: [ID:]
Further company coverage: MARK.NS
Feb 5 (Reuters) - Marksans Pharma Ltd MARK.NS:
DEC-QUARTER CONSOL NET PROFIT 1.13 BILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.54 BILLION RUPEES
Source text: [ID:]
Further company coverage: MARK.NS
India's Marksans Pharma rises after unit gets marketing approval for drug
** Shares of Marksans Pharma MARK.NS rise 2% to 192 rupees, snapping a two-day losing streak
** Pharma co's UK unit gets approval to market its product Cetirizine
** More than 570,400 shares change hands by 1:35 pm IST vs 30-day avg of 1.4 mln shares
** YTD, however, MARK is down 35%
(Reporting by Komal Salecha)
** Shares of Marksans Pharma MARK.NS rise 2% to 192 rupees, snapping a two-day losing streak
** Pharma co's UK unit gets approval to market its product Cetirizine
** More than 570,400 shares change hands by 1:35 pm IST vs 30-day avg of 1.4 mln shares
** YTD, however, MARK is down 35%
(Reporting by Komal Salecha)
India's Marksans Pharma rises after UK unit gets marketing authorisation
** Shares of Marksans Pharma MARK.NS rise 3.2% to 184 rupees, mark their biggest intraday pct gain since July 30
** Stock set to snap a seven-session losing streak, if gains hold
** The pharma co's unit gets marketing authorization from the UK MHRA for 3 metformin hydrochloride products
** Marksans stock down 38%, YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
** Shares of Marksans Pharma MARK.NS rise 3.2% to 184 rupees, mark their biggest intraday pct gain since July 30
** Stock set to snap a seven-session losing streak, if gains hold
** The pharma co's unit gets marketing authorization from the UK MHRA for 3 metformin hydrochloride products
** Marksans stock down 38%, YTD
(Reporting by Rudra Pratap Singh in Bengaluru)
India's Marksans Pharma slumps 10% as quarterly profit drops
** Marksans Pharma MARK.NS slumps 10% to four-month low of 189 rupees; set for sixth consecutive session of losses
** Stock on course for biggest daily pct drop since April 4
** Co's Q1 consolidated profit falls 34% on higher costs
** Around 3 million shares change hands so far, about 2.3x 30-day avg volume
** YTD, MARK down 36.3%
(Reporting by Vivek Kumar M)
** Marksans Pharma MARK.NS slumps 10% to four-month low of 189 rupees; set for sixth consecutive session of losses
** Stock on course for biggest daily pct drop since April 4
** Co's Q1 consolidated profit falls 34% on higher costs
** Around 3 million shares change hands so far, about 2.3x 30-day avg volume
** YTD, MARK down 36.3%
(Reporting by Vivek Kumar M)
Marksans Pharma Re-Appoints Mark Saldanha As Managing Director
July 25 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - BOARD RE-APPOINTS MARK SALDANHA AS MANAGING DIRECTOR
Source text: ID:nNSE5JHnbw
Further company coverage: MARK.NS
July 25 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - BOARD RE-APPOINTS MARK SALDANHA AS MANAGING DIRECTOR
Source text: ID:nNSE5JHnbw
Further company coverage: MARK.NS
India's Marksans Pharma gains as US FDA completes inspection at unit
** India's Marksans Pharma MARK.NS gains 3.1% to 260.60 rupees
** US FDA finishes inspection at drugmaker's manufacturing facility in New York with no observations
** MARK also gets establishment inspection report from US FDA - showing successful completion of inspection
** Stock trims YTD losses to 12%
(Reporting by Kashish Tandon in Bengaluru)
** India's Marksans Pharma MARK.NS gains 3.1% to 260.60 rupees
** US FDA finishes inspection at drugmaker's manufacturing facility in New York with no observations
** MARK also gets establishment inspection report from US FDA - showing successful completion of inspection
** Stock trims YTD losses to 12%
(Reporting by Kashish Tandon in Bengaluru)
India's Marksans Pharma rises after UK unit gets marketing authorisation
** Shares of Marksans Pharma MARK.NS rise as much as 2.3% to 256 rupees
** Stock on track to snap five-day losing streak
** Pharma co's UK unit gets marketing authorisation from regulator for oxybutynin hydrochloride oral solution to treat overactive bladder symptoms
** MARK last up 1%, cutting YTD losses to 15.7%
(Reporting by Meenakshi Maidas in Bengaluru)
** Shares of Marksans Pharma MARK.NS rise as much as 2.3% to 256 rupees
** Stock on track to snap five-day losing streak
** Pharma co's UK unit gets marketing authorisation from regulator for oxybutynin hydrochloride oral solution to treat overactive bladder symptoms
** MARK last up 1%, cutting YTD losses to 15.7%
(Reporting by Meenakshi Maidas in Bengaluru)
India's Marksans Pharma rises with Australian market entry
** India's Marksans Pharma MARK.NS rises 5%
** Co says Goa facility gets Australian nod for exports
** Stock set for third consecutive session of gains
** More than 1.7 mln shares change hands, 1.2x of 30-day avg
** Stock cuts YTD loss to ~27%
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
** India's Marksans Pharma MARK.NS rises 5%
** Co says Goa facility gets Australian nod for exports
** Stock set for third consecutive session of gains
** More than 1.7 mln shares change hands, 1.2x of 30-day avg
** Stock cuts YTD loss to ~27%
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
Marksans Pharma Says Relonchem Receives UK MHRA approval For Baclofen 10 mg Tablets
March 19 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - RELONCHEM RECEIVES UK MHRA APPROVAL FOR BACLOFEN 10 MG TABLETS
Source text: ID:nBSE8NR31v
Further company coverage: MARK.NS
March 19 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - RELONCHEM RECEIVES UK MHRA APPROVAL FOR BACLOFEN 10 MG TABLETS
Source text: ID:nBSE8NR31v
Further company coverage: MARK.NS
Marksans Pharma Ltd- Uk Unit Gets Marketing Authorization For Product Ibuprofen And Paracetamol
Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD- UK UNIT GETS MARKETING AUTHORIZATION FOR PRODUCT IBUPROFEN AND PARACETAMOL
Source text: [ID:]
Further company coverage: MARK.NS
Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD- UK UNIT GETS MARKETING AUTHORIZATION FOR PRODUCT IBUPROFEN AND PARACETAMOL
Source text: [ID:]
Further company coverage: MARK.NS
Marksans Pharma Dec-Quarter Consol Net Profit 1.05 Billion Rupees
Feb 11 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES
MARKSANS PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.82 BILLION RUPEES
Source text: ID:nBSE7GJBDX
Further company coverage: MARK.NS
Feb 11 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES
MARKSANS PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.82 BILLION RUPEES
Source text: ID:nBSE7GJBDX
Further company coverage: MARK.NS
Marksans Pharma Gets USFDA Approval For Loratadine USP 10Mg Tablets
Nov 22 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA - USFDA APPROVAL FOR LORATADINE USP 10MG TABLETS
Source text: [ID:]
Further company coverage: MARK.NS
Nov 22 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA - USFDA APPROVAL FOR LORATADINE USP 10MG TABLETS
Source text: [ID:]
Further company coverage: MARK.NS
Marksans Pharma Sept-Quarter Consol Net Profit 967.2 Million Rupees
Nov 12 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA SEPT-QUARTER CONSOL NET PROFIT 967.2 MILLION RUPEES
MARKSANS PHARMA SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES
Source text: ID:nNSE1WZ3QZ
Further company coverage: MARK.NS
Nov 12 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA SEPT-QUARTER CONSOL NET PROFIT 967.2 MILLION RUPEES
MARKSANS PHARMA SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES
Source text: ID:nNSE1WZ3QZ
Further company coverage: MARK.NS
Marksans Pharma Unit Relonchem Gets Marketing Authorization For Its Products
Aug 21 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - UNIT RELONCHEM RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS
MARKSANS PHARMA - UNIT GETS MARKETING AUTHORIZATION FOR FLUOXETINE 10MG, 30MG, 60MG CAPSULES
Source text for Eikon: [ID:]
Further company coverage: MARK.NS
Aug 21 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - UNIT RELONCHEM RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS
MARKSANS PHARMA - UNIT GETS MARKETING AUTHORIZATION FOR FLUOXETINE 10MG, 30MG, 60MG CAPSULES
Source text for Eikon: [ID:]
Further company coverage: MARK.NS
Marksans Pharma Announces Closure Of FDA Inspection At Manufacturing Facility In Goa
Aug 20 (Reuters) - Marksans Pharma Ltd MARK.NS:
CLOSURE OF FDA INSPECTION AT MANUFACTURING FACILITY IN VERNA, GOA
USFDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR MANUFACTURING FACILITY
INSPECTION CLASSIFICATION OF FACILITY IS VOLUNTARY ACTION INDICATED
Source text for Eikon: ID:nBSE427rPg
Further company coverage: MARK.NS
Aug 20 (Reuters) - Marksans Pharma Ltd MARK.NS:
CLOSURE OF FDA INSPECTION AT MANUFACTURING FACILITY IN VERNA, GOA
USFDA ISSUED ESTABLISHMENT INSPECTION REPORT FOR MANUFACTURING FACILITY
INSPECTION CLASSIFICATION OF FACILITY IS VOLUNTARY ACTION INDICATED
Source text for Eikon: ID:nBSE427rPg
Further company coverage: MARK.NS
India's Marksans Pharma rises after Q1 profit boost
** Shares of Marksans Pharma MARK.NS up 9.4% at 205.4 rupees, its steepest gain since July 24
** Pharmaceutical formulations maker's Q1 consol net profit grew ~30%, rev up 18%
** Shares see busiest day in about 3 weeks, with over 3.2 mln shares traded
** Stock up 28% YTD, vs an 81% and 9% rise in peers Natco Pharma NATP.NS and Mankind Pharma MNKI.NS, respectively
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Marksans Pharma MARK.NS up 9.4% at 205.4 rupees, its steepest gain since July 24
** Pharmaceutical formulations maker's Q1 consol net profit grew ~30%, rev up 18%
** Shares see busiest day in about 3 weeks, with over 3.2 mln shares traded
** Stock up 28% YTD, vs an 81% and 9% rise in peers Natco Pharma NATP.NS and Mankind Pharma MNKI.NS, respectively
(Reporting by Aleef Jahan in Bengaluru)
Marksans Pharma June-Quarter Consol Net Profit 887.5 Million Rupees
Aug 13 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 887.5 MILLION RUPEES
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.91 BILLION RUPEES
Source text for Eikon: ID:nBSEbkbfV1
Further company coverage: MARK.NS
Aug 13 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 887.5 MILLION RUPEES
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.91 BILLION RUPEES
Source text for Eikon: ID:nBSEbkbfV1
Further company coverage: MARK.NS
Marksans Pharma says Unit Relonchem Gets Marketing Authorization From UKMHRA
July 2 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - UNIT RELONCHEM GETS MARKETING AUTHORIZATION FROM UKMHRA
Source text for Eikon: ID:nBSE2bS85Q
Further company coverage: MARK.NS
July 2 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD - UNIT RELONCHEM GETS MARKETING AUTHORIZATION FROM UKMHRA
Source text for Eikon: ID:nBSE2bS85Q
Further company coverage: MARK.NS
Marksans Pharma March-Qtr Consol Net Profit Falls
May 30 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA MARCH-QUARTER CONSOL NET PROFIT 782.9 MILLION RUPEES VERSUS PROFIT 819.3 MILLION RUPEES
MARKSANS PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 5.6 BILLION RUPEES VERSUS 4.86 BILLION RUPEES
Further company coverage: MARK.NS
May 30 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA MARCH-QUARTER CONSOL NET PROFIT 782.9 MILLION RUPEES VERSUS PROFIT 819.3 MILLION RUPEES
MARKSANS PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 5.6 BILLION RUPEES VERSUS 4.86 BILLION RUPEES
Further company coverage: MARK.NS
India's Marksans Pharma up on UK regulator nod for unit's seizure drug
** Shares of Marksans Pharma MARK.NS rose as much as 2.8%; last up 0.9% to 166.2 rupees
** Co's unit got marketing authorisation from UK drug regulator for Levetiracetam Relonchem 100 mg/mL oral solution used in seizure treatment
** Stock on track for second straight monthly climb, up 1.5% in May after falling for four straight months through March
** Stock up ~3% YTD vs ~13% climb in Nifty Pharma index .NIPHARM, of which MARK is not a member
(Reporting by Varun Vyas in Bengaluru)
** Shares of Marksans Pharma MARK.NS rose as much as 2.8%; last up 0.9% to 166.2 rupees
** Co's unit got marketing authorisation from UK drug regulator for Levetiracetam Relonchem 100 mg/mL oral solution used in seizure treatment
** Stock on track for second straight monthly climb, up 1.5% in May after falling for four straight months through March
** Stock up ~3% YTD vs ~13% climb in Nifty Pharma index .NIPHARM, of which MARK is not a member
(Reporting by Varun Vyas in Bengaluru)
Marksans Pharma Says US FDA Inspected Goa Manufacturing Facility
April 18 (Reuters) - Marksans Pharma Ltd MARK.NS:
USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN VERNA, GOA, INDIA
COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483
THERE IS NO DATA INTEGRITY OBSERVATION
Further company coverage: MARK.NS
April 18 (Reuters) - Marksans Pharma Ltd MARK.NS:
USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN VERNA, GOA, INDIA
COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483
THERE IS NO DATA INTEGRITY OBSERVATION
Further company coverage: MARK.NS
Marksans Pharma Dec-Quarter Consol Net Profit 832.4 Million Rupees
Feb 13 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 832.4 MILLION RUPEES VERSUS 634.1 MILLION RUPEES
MARKSANS PHARMA LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.86 BILLION RUPEES VERSUS 4.8 BILLION RUPEES
Source text for Eikon: ID:nNSE9j7rXt
Further company coverage: MARK.NS
Feb 13 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 832.4 MILLION RUPEES VERSUS 634.1 MILLION RUPEES
MARKSANS PHARMA LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.86 BILLION RUPEES VERSUS 4.8 BILLION RUPEES
Source text for Eikon: ID:nNSE9j7rXt
Further company coverage: MARK.NS
India's Marksans Pharma hits record high after Q2 profit jump
** Shares of Marksans Pharma MARK.NS rise as much as 10.5% to hit a record high of 128.50 rupees
** Stock marks sharpest intraday pct gain since July 26
** The drugmaker reported a 36.3% Y/Y rise in Q2 consolidated net profit while rev from ops rose 17.3% Y/Y
** EBITDA in Q2 grew by 41.9% with an EBITDA margin of 21.4%
** Operating margins expanded, compared with prior year, and sequentially led by reduced raw material pricing and freight cost, said MD and CEO Mark Saldanha
** Stock is witnessing its most active trading session since July 12, with more than 14.3 mln shares change hands, 8x of 30-day avg
** Marksans stock up ~120% YTD
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
** Shares of Marksans Pharma MARK.NS rise as much as 10.5% to hit a record high of 128.50 rupees
** Stock marks sharpest intraday pct gain since July 26
** The drugmaker reported a 36.3% Y/Y rise in Q2 consolidated net profit while rev from ops rose 17.3% Y/Y
** EBITDA in Q2 grew by 41.9% with an EBITDA margin of 21.4%
** Operating margins expanded, compared with prior year, and sequentially led by reduced raw material pricing and freight cost, said MD and CEO Mark Saldanha
** Stock is witnessing its most active trading session since July 12, with more than 14.3 mln shares change hands, 8x of 30-day avg
** Marksans stock up ~120% YTD
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
India's Marksans Pharma up after unit gets UK approval for Vitamin B12 drug
** Shares of Marksans Pharma MARK.NS rise as much as 3.6% to 116.65 rupees apiece
** Drug maker's unit receives marketing authorisation from United Kingdom for Cyanocobalamin tablets
** Drug used to treat Vitamin B12 deficiencies and anaemia
** Trading volume is 2.87 mln shares as of 1:13 p.m. IST, nearly twice the 30-day avg - LSEG data
** Including day's gains, MARK up 99% in 2023 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
** Shares of Marksans Pharma MARK.NS rise as much as 3.6% to 116.65 rupees apiece
** Drug maker's unit receives marketing authorisation from United Kingdom for Cyanocobalamin tablets
** Drug used to treat Vitamin B12 deficiencies and anaemia
** Trading volume is 2.87 mln shares as of 1:13 p.m. IST, nearly twice the 30-day avg - LSEG data
** Including day's gains, MARK up 99% in 2023 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Marksans Pharma Says Time-Cap Laboratories Got EIR From US FDA
Nov 3 (Reuters) - Marksans Pharma Ltd MARK.NS:
TIME-CAP LABORATORIES, INC, RECEIVES ESTABLISHMENT INSPECTION REPORT FROM US FDA
NO 483' S WERE ISSUED DURING THE AUDIT
Source text for Eikon: ID:nNSE3Ymvl2
Further company coverage: MARK.NS
Nov 3 (Reuters) - Marksans Pharma Ltd MARK.NS:
TIME-CAP LABORATORIES, INC, RECEIVES ESTABLISHMENT INSPECTION REPORT FROM US FDA
NO 483' S WERE ISSUED DURING THE AUDIT
Source text for Eikon: ID:nNSE3Ymvl2
Further company coverage: MARK.NS
India's Marksans Pharma up on German health authorities' clearance to Goa facility
** Shares of Marksans Pharma MARK.NS rise as much as 5.8% to 111.70 rupees
** Drugmaker says its manufacturing facility in Goa has successfully undergone inspection from German health authorities
** The German authorities have not found any critical/major observations, but have a few recommendations/minor points- Marksans
** Stock on track for a third consecutive session of gains, if trends hold
** More than 2.2 mln shares change hands by 12:17 p.m. IST, 1.6x the 30-day avg
** Stock last up 5.1%, bumping YTD gains to 90.2%
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
** Shares of Marksans Pharma MARK.NS rise as much as 5.8% to 111.70 rupees
** Drugmaker says its manufacturing facility in Goa has successfully undergone inspection from German health authorities
** The German authorities have not found any critical/major observations, but have a few recommendations/minor points- Marksans
** Stock on track for a third consecutive session of gains, if trends hold
** More than 2.2 mln shares change hands by 12:17 p.m. IST, 1.6x the 30-day avg
** Stock last up 5.1%, bumping YTD gains to 90.2%
(Reporting by Ashish Chandra in Bengaluru)
((ashish.chandra@thomsonreuters.com (+91 7982114624))
Marksans Pharma Gets US FDA Approval For Esomeprazole Magnesium Delayed-Release Capsules Usp, 20 Mg (Otc)
Oct 3 (Reuters) - Marksans Pharma Ltd MARK.NS:
US FDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG (OTC)
Further company coverage: MARK.NS
Oct 3 (Reuters) - Marksans Pharma Ltd MARK.NS:
US FDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG (OTC)
Further company coverage: MARK.NS
Marksans Pharma Receives USFDA Approval For Guaifenesin Extended-Release Tablets
Aug 22 (Reuters) - Marksans Pharma Ltd MARK.NS:
RECEIVES USFDA APPROVAL FOR GUAIFENESIN EXTENDED-RELEASE TABLETS
Source text for Eikon: [ID:]
Further company coverage: MARK.NS
Aug 22 (Reuters) - Marksans Pharma Ltd MARK.NS:
RECEIVES USFDA APPROVAL FOR GUAIFENESIN EXTENDED-RELEASE TABLETS
Source text for Eikon: [ID:]
Further company coverage: MARK.NS
Marksans Pharma Ltd June-Quarter Consol Net Profit 686.6 Million Rupees
Aug 11 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 686.6 MILLION RUPEES VERSUS 597.2 MILLION RUPEES
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5 BILLION RUPEES VERSUS 4.34 BILLION RUPEES
Source text for Eikon: ID:nBSE5zjTZf
Further company coverage: MARK.NS
Aug 11 (Reuters) - Marksans Pharma Ltd MARK.NS:
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 686.6 MILLION RUPEES VERSUS 597.2 MILLION RUPEES
MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5 BILLION RUPEES VERSUS 4.34 BILLION RUPEES
Source text for Eikon: ID:nBSE5zjTZf
Further company coverage: MARK.NS
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Marksans Pharma do?
Marksans Pharma is an Indian pharmaceutical company with a global presence, excelling in research, manufacturing, and marketing of finished dosage pharmaceutical formulations. Their focus areas include a wide range of OTC & prescription drugs across various fields.
Who are the competitors of Marksans Pharma?
Marksans Pharma major competitors are Sanofi India, Procter&Gamble Healt, Viyash Scientific, Strides Pharma Scien, FDC, Zota Health Care, Caplin Point Lab. Market Cap of Marksans Pharma is ₹7,620 Crs. While the median market cap of its peers are ₹7,919 Crs.
Is Marksans Pharma financially stable compared to its competitors?
Marksans Pharma seems to be less financially stable compared to its competitors. Altman Z score of Marksans Pharma is 8.79 and is ranked 4 out of its 8 competitors.
Does Marksans Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Marksans Pharma latest dividend payout ratio is 9.53% and 3yr average dividend payout ratio is 8.9%
How has Marksans Pharma allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory
How strong is Marksans Pharma balance sheet?
Balance sheet of Marksans Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Marksans Pharma improving?
The profit is oscillating. The profit of Marksans Pharma is ₹362 Crs for TTM, ₹381 Crs for Mar 2025 and ₹314 Crs for Mar 2024.
Is the debt of Marksans Pharma increasing or decreasing?
Yes, The net debt of Marksans Pharma is increasing. Latest net debt of Marksans Pharma is -₹643.14 Crs as of Sep-25. This is greater than Mar-25 when it was -₹1,385.3 Crs.
Is Marksans Pharma stock expensive?
Marksans Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Marksans Pharma is 21.15, while 3 year average PE is 20.42. Also latest EV/EBITDA of Marksans Pharma is 13.14 while 3yr average is 13.39.
Has the share price of Marksans Pharma grown faster than its competition?
Marksans Pharma has given better returns compared to its competitors. Marksans Pharma has grown at ~21.42% over the last 8yrs while peers have grown at a median rate of 11.14%
Is the promoter bullish about Marksans Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Marksans Pharma is 43.87% and last quarter promoter holding is 43.87%.
Are mutual funds buying/selling Marksans Pharma?
The mutual fund holding of Marksans Pharma is increasing. The current mutual fund holding in Marksans Pharma is 4.41% while previous quarter holding is 3.92%.